![Jennifer McNealey](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jennifer McNealey
Directeur Financier/CFO chez
Abdera Therapeutics, Inc.
Profil
Jennifer Isacoff McNealey is the founder of Laurient LLC, which was founded in 2005.
She is currently the Chief Financial Officer at Abdera Therapeutics, Inc. since 2023.
In her former positions, she served as an Independent Director at Enzon Pharmaceuticals, Inc. from 2013 to 2021, as well as at Antibe Therapeutics, Inc. from 2020 to 2024, and at Conduit Pharmaceuticals, Inc. from 2023 to 2024.
She also held roles as an Analyst at Amerindo Investment Advisors, Inc., a Portfolio Manager at Paramount Capital, Inc., an Analyst at Franklin Advisers, Inc., and a Research Analyst at Weiss, Peck & Greer LLC.
Additionally, she worked as a Portfolio Manager at Morgan Stanley Dean Witter Advisors, Inc. Ms. McNealey served as the Chief Financial Officer at Telesis Bio, Inc. from 2015 to 2022 and as the Vice President-Investor Relations & Strategy at Calithera Biosciences, Inc. from 2016 to 2021.
She completed her undergraduate and graduate degrees at Cornell University in 1995 and 1997, respectively.
Postes actifs de Jennifer McNealey
| Sociétés | Poste | Début |
|---|---|---|
Abdera Therapeutics, Inc.
 Abdera Therapeutics, Inc. Packaged SoftwareTechnology Services Develops precision radiotherapeutics platform | Directeur Financier/CFO | 01/01/2023 |
Anciens postes connus de Jennifer McNealey
| Sociétés | Poste | Fin |
|---|---|---|
| CDT EQUITY INC. | Directeur/Membre du Conseil | 13/05/2024 |
| ANTIBE THERAPEUTICS INC. | Directeur/Membre du Conseil | 01/01/2024 |
| TELESIS BIO, INC. | Directeur Financier/CFO | 08/07/2022 |
Enzon Pharmaceuticals, Inc.
 Enzon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative therapeutics for cancer patients | Directeur/Membre du Conseil | 01/11/2021 |
| CALITHERA BIOSCIENCES, INC. | Investor Relations Contact | 01/03/2021 |
Formation de Jennifer McNealey
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
93
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Enzon Pharmaceuticals, Inc.
Enzon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative therapeutics for cancer patients | Health Technology |
Amerindo Investment Advisors, Inc.
 Amerindo Investment Advisors, Inc. Investment ManagersFinance Amerindo's investment objective is long-term capital appreciation. This investment approach focuses on those sectors of emerging growth technology that they believe will be responsible for producing the next major wave of economic growth. The investment team continually searches for relatively new public companies in their sectors with substantial growth potential. Portfolios are constructed with concentrated initial positions in a limited number of stocks. Amerindo's investment process begins by determining the fastest growing end-user markets in technology and science with the greatest potential, then identifying the leading companies in those markets leveraging off the work of the best venture capitalists, investment bankers and industry experts. The firm then determines if the management, technology and market are able to produce a successful company dominating its industry that will give rise to a sustainable period of growth. Amerindo re-invests maturing positions and starts the process again. Amerindo may sell when a significant change in the company's vision takes place, management missteps or there is a negative major market or technology shift. It has always been Amerindo's strategy to invest in young technology companies during their most dynamic growth phase. Typically after a 3 to 5 year period, they believe a successful emerging technology company will see its early explosive growth rates begin to moderate. At this juncture Amerindo would be looking into other faster growing candidates to re-deploy its investment funds. | Finance |
Paramount Capital, Inc. | |
Franklin Advisers, Inc.
 Franklin Advisers, Inc. Investment ManagersFinance Franklin Advisers provides advisory services to a range of products and separate accounts which utilize various investment strategies including equity, fixed income, core, hybrid, and multi-asset strategies. The firm employs fundamental, bottom-up investment analysis to select securities within a specific sector or industry. | Finance |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Weiss, Peck & Greer LLC
 Weiss, Peck & Greer LLC Investment Banks/BrokersFinance Security Brokers Dealers And Flotation Companies | Finance |
Morgan Stanley Dean Witter Advisors, Inc.
 Morgan Stanley Dean Witter Advisors, Inc. Financial ConglomeratesFinance Provides financial services | Finance |
Calithera Biosciences, Inc.
 Calithera Biosciences, Inc. BiotechnologyHealth Technology Develops novel therapeutics to control cancer and other diseases | Health Technology |
Antibe Therapeutics, Inc.
 Antibe Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops pain and inflammation drugs | Health Technology |
Laurient LLC | |
Telesis Bio, Inc.
 Telesis Bio, Inc. Medical SpecialtiesHealth Technology Engages in R&D, manufacturing and sale of synthetic biology instruments | Health Technology |
Abdera Therapeutics, Inc.
Abdera Therapeutics, Inc. Packaged SoftwareTechnology Services Develops precision radiotherapeutics platform | Technology Services |
Conduit Pharmaceuticals, Inc.
 Conduit Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage specialty biopharmaceutical company | Health Technology |
